Biotechnology News and Research

RSS

Marqibo now available to leukemia patients through myTomorrows' Internet-based platform

myTomorrows (Amsterdam, the Netherlands), announced today that it has started a collaboration with Spectrum Pharmaceuticals, Inc. (Henderson, USA) to provide access to its liposome-encapsulated vincristine for treatment of Philadelphia chromosome negative acute lymphoblastic leukemia.

10 Dec 2015

Palatin achieves patient enrollment target in pivotal phase 3 studies of bremelanotide for FSD treatment

Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced it has achieved its patient enrollment target in its two pivotal phase 3 clinical studies of bremelanotide for the treatment of female sexual dysfunction (FSD).

10 Dec 2015

Human heart can fully recover after massive damage

The scientists report the case of a newborn that had suffered a massive heart attack in the first hours of life. It was caused by a blockage in a vital coronary vessel. "The baby's heart was severely damaged. Astonishingly, the baby recovered very quickly," said Bernhard Haubner, a cardiologist and researcher, and his colleague, Johanna Schneider, in an article just published in the journal "Circulation Research".

10 Dec 2015

Renowned experts, Nobel laureates to convene at Toulouse Onco Week to discuss latest advances in oncology

The first Toulouse Onco Week (TOW) is due to take place from 3 to 6 February 2016 at the Pierre Baudis Congess Center, Toulouse, France. This unique event will be focused on the international fight against cancer by bringing together stakeholders from around the world and presenting the latest global innovations in oncology.

10 Dec 2015

OncoSec reports net loss of $7.0 million for first quarter of fiscal 2016

OncoSec Medical Incorporated, a company developing DNA-based intratumoral cancer immunotherapies, today announced financial results for the first quarter of fiscal year ended July 31, 2016.

8 Dec 2015

Study provides new insights into relationship between taste, behavior

Evolutionary conserved brainstem circuits are the first relay for gustatory information in the vertebrate brain. While the brainstem circuits act as our life support system and they mediate vital taste related behaviors, the principles of gustatory computations in these circuits are poorly understood.

8 Dec 2015

Dompé’s investigational biotech molecule receives orphan drug designation for treatment of neurotrophic keratitis

The Dompé biopharmaceutical company announced today that the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA) has officially designated recombinant human Nerve Growth Factor (rhNGF) - the investigational biotech molecule developed by Dompé based on research by Nobel Laureate Rita Levi Montalcini - as an orphan drug for the treatment of neurotrophic keratitis.

8 Dec 2015

BioAtla, Pfizer sign license and option agreement for new class of antibody therapeutics

BioAtla LLC, a biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that it has entered into a license and option agreement with Pfizer Inc. to advance the development and commercialization of a new class of antibody therapeutics based on BioAtla's CAB platform and utilizing Pfizer's proprietary antibody drug conjugate (ADC) payloads.

8 Dec 2015

Phase 1 BelCHOP study shows belinostat and CHOP chemo regimen as first-line treatment for PTCL

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations and a primary focus in Hematology and Oncology, and Onxeo S.A., an innovative company specializing in the development of orphan oncology drugs, today jointly announced the results from their Phase 1 combination trial of belinostat (Beleodaq) with the CHOP (Cyclophosphamide, Hydroxyl-doxorubicin; Vincristine, and Prednisone) chemotherapy regimen as first-line treatment for newly diagnosed peripheral T-cell lymphoma (PTCL).

8 Dec 2015

Researchers reveal potential for exploring new treatment options for triple-negative breast cancer

Researchers from Caris Life Sciences and Fox Chase Cancer Center – Temple Health announced the presentation of two studies revealing the potential for exploring new therapeutic options for triple-negative breast cancer (TNBC) at the 2015 San Antonio Breast Cancer Symposium.

7 Dec 2015

Bacteriophage therapy: an alternative to antibiotics? An interview Professor Clokie

A phage is a virus that infects a bacterium. People often get very confused about what the difference is between a virus and a bacterium. A virus, like a bacterium, is also a microorganism, but unlike bacteria, it needs to have a host to be able to replicate and propagate.

2 Dec 2015

The Importance of Flexibility in Spectrophotometry

News-Medical speaks to Jessica Geisler about the need for flexible spectrophotometers that can handle a range of measurement types.

From Eppendorf 1 Dec 2015

Novel class of antimicrobials could be effective in fighting drug-resistant MRSA infection

A novel class of antimicrobials that inhibits the function of a key disease-causing component of bacteria could be effective in fighting methicillin-resistant Staphylococcus aureus (MRSA), one of the major drug-resistant bacterial pathogens, according to researchers at Georgia State University.

1 Dec 2015

Research sheds light on genetic factors involved in autoimmune diseases

A collaboration between researchers at the Babraham Institute and the University of Manchester has mapped the physical connections occurring in the genome to shed light on the parts of the genome involved in autoimmune diseases. Using a new technique, called Capture Hi-C, the team revealed novel insights into how changes in the genetic sequence have a biological effect and increase the risk of disease.

30 Nov 2015

Human Longevity announces acquisition of Cypher Genomics

Human Longevity, Inc., the genomics-based, technology-driven company, announced today that the company has acquired Cypher Genomics, Inc., a leading genome informatics company offering highly accurate, rapid and robust human genomic interpretation software solutions.

30 Nov 2015

Seaweed extract shows promise in treating H. pylori-related diseases, gastric cancer

A unique seaweed extract shows promise for the treatment of Helicobacter pylori-related diseases and gastric cancer, according to new research undertaken at the University of Western Australia.

28 Nov 2015

Can-Fite BioPharma reports financial results, provides updates on drug development programs

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today reported financial results for the nine months ended September 30, 2015 and updates on its drug development programs.

27 Nov 2015

Discovery opens up new avenue for research on potential treatments for Alzheimer's disease

A team of researchers led by UNSW Australia scientists has discovered how connections between brain cells are destroyed in the early stages of Alzheimer's disease - work that opens up a new avenue for research on possible treatments for the degenerative brain condition.

27 Nov 2015

Researchers reveal new technique to grow human hepatocytes in the laboratory

In new research appearing in the prestigious journal Nature Biotechnology, an international research team led by The Hebrew University of Jerusalem describes a new technique for growing human hepatocytes in the laboratory. This groundbreaking development could help advance a variety of liver-related research and applications, from studying drug toxicity to creating bio-artificial liver support for patients awaiting transplantations.

27 Nov 2015

Allergan, Rugen Therapeutics collaborate to discover and develop novel therapies for ASD and OCD

Allergan plc, a leading global pharmaceutical company, and Rugen Therapeutics, a start-up biotechnology company focused on the development of novel treatments for unmet CNS disorders and funded by the F-Prime Biomedical Research Initiative, today announced that they have entered into an exclusive collaboration to support the discovery and development of novel therapies for Autism Spectrum Disorders (ASD) and Obsessive Compulsive disorders (OCD).

25 Nov 2015

Biotechnology News and Research

Marqibo now available to leukemia patients through myTomorrows' Internet-based platform

Palatin achieves patient enrollment target in pivotal phase 3 studies of bremelanotide for FSD treatment

Human heart can fully recover after massive damage

Renowned experts, Nobel laureates to convene at Toulouse Onco Week to discuss latest advances in oncology

OncoSec reports net loss of $7.0 million for first quarter of fiscal 2016

Study provides new insights into relationship between taste, behavior

Dompé’s investigational biotech molecule receives orphan drug designation for treatment of neurotrophic keratitis

BioAtla, Pfizer sign license and option agreement for new class of antibody therapeutics

Phase 1 BelCHOP study shows belinostat and CHOP chemo regimen as first-line treatment for PTCL

Researchers reveal potential for exploring new treatment options for triple-negative breast cancer

Bacteriophage therapy: an alternative to antibiotics? An interview Professor Clokie

The Importance of Flexibility in Spectrophotometry

Novel class of antimicrobials could be effective in fighting drug-resistant MRSA infection

Research sheds light on genetic factors involved in autoimmune diseases

Human Longevity announces acquisition of Cypher Genomics

Seaweed extract shows promise in treating H. pylori-related diseases, gastric cancer

Can-Fite BioPharma reports financial results, provides updates on drug development programs

Discovery opens up new avenue for research on potential treatments for Alzheimer's disease

Researchers reveal new technique to grow human hepatocytes in the laboratory

Allergan, Rugen Therapeutics collaborate to discover and develop novel therapies for ASD and OCD

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News